Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Center for Advancing Clinical and Translational Sciences, National Cerebral and Cardiovascular Center, Suita, Japan.
Hypertens Res. 2023 Jan;46(1):75-83. doi: 10.1038/s41440-022-01046-4. Epub 2022 Oct 13.
The effects of acute systolic blood pressure levels achieved with continuous intravenous administration of nicardipine for Japanese patients with acute intracerebral hemorrhage on clinical outcomes were determined. A systematic review and individual participant data analysis of articles were performed based on prospective studies involving adults developing hyperacute intracerebral hemorrhage who were treated with intravenous nicardipine. Outcomes included death or disability at 90 days, defined as the modified Rankin Scale score of 4-6, and hematoma expansion, defined as an increase 6 mL or more from baseline to 24 h computed tomography. Of the total 499 Japanese patients (age 64.9 ± 11.8 years, 183 women, initial BP 203.5 ± 18.3/109.1 ± 17.2 mmHg) studied, death or disability occurred in 35.6%, and hematoma expansion occurred in 15.6%. Mean hourly systolic blood pressure during the initial 24 h was positively associated with death or disability (adjusted odds ratio 1.25, 95% confidence interval 1.03-1.52 per 10 mmHg) and hematoma expansion (1.49, 1.18-1.87). These odds ratios were relatively high as compared to the reported ones for overall global patients of this individual participant data analysis [1.12 (95% confidence interval 1.00-1.26) and 1.16 (1.02-1.32), respectively]. In conclusion, lower levels of systolic blood pressure by continuous intravenous nicardipine were associated with lower risks of hematoma expansion and 90-day death or disability in Japanese patients with hyperacute intracerebral hemorrhage. The impact of systolic blood pressure lowering on better outcome seemed to be stronger in Japanese patients than the global ones.
本研究旨在探讨尼卡地平持续静脉输注对急性脑出血日本患者急性收缩压水平变化对临床结局的影响。我们对涉及接受静脉尼卡地平治疗的超急性脑出血成人患者的前瞻性研究进行了系统评价和个体参与者数据分析。研究结局包括 90 天时的死亡或残疾(定义为改良 Rankin 量表评分为 4-6 分)和血肿扩大(定义为基线至 24 小时计算机断层扫描时增加 6ml 或更多)。在总共 499 例日本患者(年龄 64.9±11.8 岁,183 例女性,初始血压 203.5±18.3/109.1±17.2mmHg)中,35.6%发生死亡或残疾,15.6%发生血肿扩大。初始 24 小时内平均每小时收缩压与死亡或残疾(校正比值比 1.25,95%置信区间 1.03-1.52/每 10mmHg)和血肿扩大(1.49,1.18-1.87)呈正相关。与本个体参与者数据分析中全球患者的报告相比,这些比值比相对较高[分别为 1.12(95%置信区间 1.00-1.26)和 1.16(1.02-1.32)]。总之,尼卡地平持续静脉输注使收缩压水平降低与日本超急性脑出血患者血肿扩大和 90 天死亡或残疾风险降低相关。降低收缩压对改善结局的影响在日本患者中似乎比全球患者更强。